Arbutus Biopharma's Entire Board Replaced as New CEO Steps In

Dow Jones

02-25

By Dean Seal

All seven members of Arbutus Biopharma's board have resigned and been replaced by five new members, including the company's new chief executive.

The virology-focused biotech company said Tuesday that Lindsay Androski, chief of the nonprofit Roivant Social Ventures, is now the company's chief executive and chairperson of the board.

Androski takes over for Michael McElhaugh, who had been serving as interim CEO since the retirement of William Collier at the end of 2023.

McElhaugh, Chairperson Frank Torti and fellow directors Daniel Burgess, Richard Henriques, Keith Manchester, James Meyers and Melissa Rewolinski have all stepped down from the board. Their departures weren't the result of a disagreement with the company or any matters relating to its operations, policies or practices, according to a securities filing.

Robert Alan Beardsley, Joseph Bishop, Matthew Gline and Anuj Hasija have been appointed to take their place on the board, which has been reduced to five members, with Androski at the helm. Arbutus said it is open to bringing on more directors and may expand the board in the coming months.

Arbutus said it will temporarily stop participating in investor meetings and conferences while the new leadership reviews development plans and strategic options for the company's hepatitis B programs.

Write to Dean Seal at dean.seal@wsj.com

(END) Dow Jones Newswires

February 25, 2025 07:47 ET (12:47 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2514099426"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2514099426\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2514099426?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-25 20:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2514099426","market":"sg","top_or_hot":-1,"title":"Arbutus Biopharma's Entire Board Replaced as New CEO Steps In","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Dean Seal \n</p>\n<pre>\n \n</pre>\n<p>\n  All seven members of Arbutus Biopharma's board have resigned and been replaced by five new members, including the company's new chief executive. \n</p>\n<p>\n  The virology-focused biotech company said Tuesday that Lindsay Androski, chief of the nonprofit Roivant Social Ventures, is now the company's chief executive and chairperson of the board. \n</p>\n<p>\n  Androski takes over for Michael McElhaugh, who had been serving as interim CEO since the retirement of William Collier at the end of 2023. \n</p>\n<p>\n  McElhaugh, Chairperson Frank Torti and fellow directors Daniel Burgess, Richard Henriques, Keith Manchester, James Meyers and Melissa Rewolinski have all stepped down from the board. Their departures weren't the result of a disagreement with the company or any matters relating to its operations, policies or practices, according to a securities filing. \n</p>\n<p>\n  Robert Alan Beardsley, Joseph Bishop, Matthew Gline and Anuj Hasija have been appointed to take their place on the board, which has been reduced to five members, with Androski at the helm. Arbutus said it is open to bringing on more directors and may expand the board in the coming months. \n</p>\n<p>\n  Arbutus said it will temporarily stop participating in investor meetings and conferences while the new leadership reviews development plans and strategic options for the company's hepatitis B programs. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 25, 2025 07:47 ET (12:47 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Arbutus Biopharma's Entire Board Replaced as New CEO Steps In</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArbutus Biopharma's Entire Board Replaced as New CEO Steps In\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-02-25 20:47</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Dean Seal \n</p>\n<pre>\n \n</pre>\n<p>\n  All seven members of Arbutus Biopharma's board have resigned and been replaced by five new members, including the company's new chief executive. \n</p>\n<p>\n  The virology-focused biotech company said Tuesday that Lindsay Androski, chief of the nonprofit Roivant Social Ventures, is now the company's chief executive and chairperson of the board. \n</p>\n<p>\n  Androski takes over for Michael McElhaugh, who had been serving as interim CEO since the retirement of William Collier at the end of 2023. \n</p>\n<p>\n  McElhaugh, Chairperson Frank Torti and fellow directors Daniel Burgess, Richard Henriques, Keith Manchester, James Meyers and Melissa Rewolinski have all stepped down from the board. Their departures weren't the result of a disagreement with the company or any matters relating to its operations, policies or practices, according to a securities filing. \n</p>\n<p>\n  Robert Alan Beardsley, Joseph Bishop, Matthew Gline and Anuj Hasija have been appointed to take their place on the board, which has been reduced to five members, with Androski at the helm. Arbutus said it is open to bringing on more directors and may expand the board in the coming months. \n</p>\n<p>\n  Arbutus said it will temporarily stop participating in investor meetings and conferences while the new leadership reviews development plans and strategic options for the company's hepatitis B programs. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 25, 2025 07:47 ET (12:47 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABUS","symbol_name":"Arbutus Biopharma Corporation","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2514099426","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2514099426","pubTimestamp":1740487620,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"All seven members of Arbutus Biopharma's board have resigned and been replaced by five new members, including the company's new chief executive.The virology-focused biotech company said Tuesday that Lindsay Androski, chief of the nonprofit Roivant Social Ventures, is now the company's chief executive and chairperson of the board.Androski takes over for Michael McElhaugh, who had been serving as interim CEO since the retirement of William Collier at the end of 2023.McElhaugh, Chairperson Frank Torti and fellow directors Daniel Burgess, Richard Henriques, Keith Manchester, James Meyers and Melissa Rewolinski have all stepped down from the board. Their departures weren't the result of a disagreement with the company or any matters relating to its operations, policies or practices, according to a securities filing.Robert Alan Beardsley, Joseph Bishop, Matthew Gline and Anuj Hasija have been appointed to take their place on the board, which has been reduced to five members, with Androski at","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ABUS":"Arbutus Biopharma Corporation"},"translate_title":"Arbutus Biopharma的整个董事会被更换，新任首席执行官上任","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABUS":1},"content_text":"By Dean Seal \n\n\n \n\n\n  All seven members of Arbutus Biopharma's board have resigned and been replaced by five new members, including the company's new chief executive. \n\n\n  The virology-focused biotech company said Tuesday that Lindsay Androski, chief of the nonprofit Roivant Social Ventures, is now the company's chief executive and chairperson of the board. \n\n\n  Androski takes over for Michael McElhaugh, who had been serving as interim CEO since the retirement of William Collier at the end of 2023. \n\n\n  McElhaugh, Chairperson Frank Torti and fellow directors Daniel Burgess, Richard Henriques, Keith Manchester, James Meyers and Melissa Rewolinski have all stepped down from the board. Their departures weren't the result of a disagreement with the company or any matters relating to its operations, policies or practices, according to a securities filing. \n\n\n  Robert Alan Beardsley, Joseph Bishop, Matthew Gline and Anuj Hasija have been appointed to take their place on the board, which has been reduced to five members, with Androski at the helm. Arbutus said it is open to bringing on more directors and may expand the board in the coming months. \n\n\n  Arbutus said it will temporarily stop participating in investor meetings and conferences while the new leadership reviews development plans and strategic options for the company's hepatitis B programs. \n\n\n \n\n\n  Write to Dean Seal at dean.seal@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 25, 2025 07:47 ET (12:47 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}